Institution Notes

Roswell Park Cancer Institute names new president, CEO

Candace S. Johnson, PhD, has been named president and CEO of Roswell Park Cancer Institute.

Johnson, who joined Roswell Park’s faculty in February 2002, is the first female leader of the 117-year-old comprehensive cancer center.

Candace Johnson

Candace S. Johnson

She succeeds Donald L. Trump, MD, FACP.

Trump — HemOnc Today’s Associate Editor for Medical Oncology — retired from Roswell Park last fall. He later became CEO and executive director of Inova Cancer Care and Research Institute, which serves Northern Virginia and Washington, D.C.

“Over the last few months, we have met some highly qualified cancer leaders from around the country who were interested in pursuing this job,” Michael Joseph, chair of the Roswell Park Cancer Institute’s board of directors, said in a press release. “There wasn’t a member of the board, community leader, RPCI employee or cancer center friend who hasn’t realized that our future leader was right in front of us. Dr. Johnson is a respected scientist and leader.” 

Johnson most recently served as Roswell Park’s deputy director and chair of the department of pharmacology and therapeutics, the Wallace family chair for translational research and professor of oncology. Since November 2014, she has also served as cancer center director for the Institute.

“Roswell Park Cancer Institute is one of the founding organizations of Buffalo,” Johnson said. “The community and state leaders who established this cancer center and built this region’s center of excellence deserve to have their legacy continue. I am committed to creating an organization and institute culture that allows our region to take pride in having a leading cancer center in its midst — one that continues to generate discoveries that diminish the burden that cancer places on our loved ones and friends throughout the world.”

Prior to joining Roswell Park, Johnson served as deputy director of basic research at the University of Pittsburgh Cancer Institute, and professor of pharmacology and medicine at the University of Pittsburgh School of Medicine.

Candace S. Johnson, PhD, has been named president and CEO of Roswell Park Cancer Institute.

Johnson, who joined Roswell Park’s faculty in February 2002, is the first female leader of the 117-year-old comprehensive cancer center.

Candace Johnson

Candace S. Johnson

She succeeds Donald L. Trump, MD, FACP.

Trump — HemOnc Today’s Associate Editor for Medical Oncology — retired from Roswell Park last fall. He later became CEO and executive director of Inova Cancer Care and Research Institute, which serves Northern Virginia and Washington, D.C.

“Over the last few months, we have met some highly qualified cancer leaders from around the country who were interested in pursuing this job,” Michael Joseph, chair of the Roswell Park Cancer Institute’s board of directors, said in a press release. “There wasn’t a member of the board, community leader, RPCI employee or cancer center friend who hasn’t realized that our future leader was right in front of us. Dr. Johnson is a respected scientist and leader.” 

Johnson most recently served as Roswell Park’s deputy director and chair of the department of pharmacology and therapeutics, the Wallace family chair for translational research and professor of oncology. Since November 2014, she has also served as cancer center director for the Institute.

“Roswell Park Cancer Institute is one of the founding organizations of Buffalo,” Johnson said. “The community and state leaders who established this cancer center and built this region’s center of excellence deserve to have their legacy continue. I am committed to creating an organization and institute culture that allows our region to take pride in having a leading cancer center in its midst — one that continues to generate discoveries that diminish the burden that cancer places on our loved ones and friends throughout the world.”

Prior to joining Roswell Park, Johnson served as deputy director of basic research at the University of Pittsburgh Cancer Institute, and professor of pharmacology and medicine at the University of Pittsburgh School of Medicine.